Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes.

Compared with insulin treatment alone, treatment with DPP-IVi/INS improved HbA1c, FBG, and 2hPPG without increasing the risk of hypoglycemia, AEs, or SAEs.